Explore our certified manufacturing and experimental development programs, engineered to bring raw medicinal botanicals into standardized, commercially reproducible therapeutic ingredients.
The global pharmaceutical and nutraceutical landscape is experiencing a paradigm shift toward evidence-based botanical remedies. However, botanical active ingredient development presents complex hurdles: batch-to-batch variation, complex secondary metabolite matrices, trace pesticide residues, and strict regulatory frameworks spanning US FDA Botanical Drug Guidance, EMA Herbal Monograph standards, and WHO GMP directives.
MedGence (Yineng Pharma), headquartered in the national biological hub of Changsha, China, provides an integrated contract research, development, and manufacturing organization (CRO/CDMO) platform. By combining centuries-old Traditional Chinese Medicine (TCM) insights with ultra-high-resolution analytics (UPLC-MS/MS, GC-MS, HPTLC) and GLP-certified pharmacology, we enable global brands to engineer natural compounds with reproducible chemical fingerprints and verified bioactivity.
| Critical Quality Attribute (CQA) | Standard Commercial Extract | MedGence Pharmaceutical Grade |
|---|---|---|
| Secondary Metabolite Titration | Single-marker nominal assay | Multi-marker quantitative profiling (HPLC/UPLC) |
| Chromatographic Fingerprint Match | < 85% batch similarity | ≥ 98.5% similarity across four seasons |
| Pesticide & Heavy Metal Limits | Standard food threshold | Compliant with USP <561>, EP 2.8.13, FDA Botanical IND |
| Biological Mechanism Validation | Literature citation only | In vitro target screening & validated animal models |
| Data Integrity & Audit Trail | Basic Certificate of Analysis | Complete GLP/GMP batch records & audit trails |
Demonstrated operational track record over 14+ years supporting pharmaceutical corporations, top-tier research hospitals, and global ingredient distributors.
From initial phytochemistry identification to regulatory dossier approval and industrial-scale manufacturing, our technical nodes support every phase of natural medicine lifecycle management.
Unlocking plant bio-diversity via high-throughput chemical screening. We separate bioactive fractions (polysaccharides, flavonoids, triterpenoid saponins, alkaloids) and isolate lead structures tailored to specified therapeutic mechanisms.
Medicinal secondary metabolites fluctuate based on terroir, microclimate, soil composition, and harvest windows. We map chromatographic profiles across regional geographies and seasonal cycles to establish optimal sourcing windows.
Establishing comprehensive qualitative and quantitative chromatographic assay methodologies. We build fully validated testing protocols complying with pharmacopeia monographs (USP, EP, ChP).
Overcoming botanical processing challenges: optimizing temperature-controlled counter-current extraction, macroporous resin column chromatography, molecular distillation, and spray-drying protocols.
Meeting international criteria for consumer safety and drug trial authorisations. We design thorough in vitro and animal safety assessment batteries.
Navigating human evidence requirements. We coordinate Phase I dose escalation and pharmacokinetics, Phase II/III randomized controlled trials, and post-market safety surveillance programs.
Why Tier-1 international pharmaceutical, cosmetic, and nutraceutical enterprises anchor their contract development and ingredient procurement within China’s upstream ecosystem.
China possesses over 11,146 medicinal plant species spanning sub-tropical, alpine, and temperate biomes. Sourcing through local Chinese specialized CDMOs provides raw material availability, eliminating multi-layered intermediaries and ensuring verifiable origin traceability from source GAP plantations.
Unlike novel synthetic scaffolds that face unpredictable in vivo safety hurdles, traditional Chinese botanical formulations provide historical empirical safety records across hundreds of years. We translate empirical records into modern scientific dossiers, reducing preclinical attrition rates.
China maintains complete end-to-end infrastructure for botanical manufacturing: primary cleaning, low-temperature micro-milling, solvent reflux, continuous chromatographic resins, spray-drying towers, and dosage encapsulators, delivering cost-competitive unit economics.
Navigating cross-border regulatory demands requires customized documentation matrices. MedGence acts as a technical partner, assisting overseas purchasers in formatting dossiers according to destination requirements.
We operate under an entrusted contract model protecting our global partners' intellectual property:
Engineered raw materials and finished formulations tailored to satisfy diverse formulation, sensory, and biological stability constraints.
High-density, water-soluble botanical extracts optimized for bio-absorption. Ideal for tablets, hard capsules, softgels, functional beverages, and effervescent delivery formats without off-putting bitterness.
Isolated active molecules (purity ≥ 98.0%) serving as chemical starting materials or active pharmaceutical ingredients (APIs) for cardiovascular, anti-inflammatory, and metabolic disease pathways.
Plant-derived polyphenol and peptide complexes standardized for transdermal penetration, anti-oxidation, melanogenesis suppression, and barrier repair, backed by cell viability assays.
Registered hospital internal preparations, ready-to-use granules, and standardized TCM concentrated decoctions fulfilling institutional quality monographs and rapid therapeutic delivery.
Strategic modernization transforming conventional herbal extraction into precision natural pharmacology.
Utilizing computational network pharmacology, machine learning docking models, and multi-omics profiling to decode multi-target botanical formulas, predicting clinical efficacy before laboratory synthesis.
Migrating away from traditional open solvent systems to closed super-critical CO2 fluid extraction, ultrasonic continuous counter-current pipelines, and enzymatic cell-wall disruption, boosting yields while cutting carbon footprints.
Overcoming botanical solubility and metabolic breakdown through self-microemulsifying drug delivery systems (SMEDDS), cyclodextrin inclusion, and phytosome encapsulation for improved systemic bioavailability.
Our research and contract manufacturing platforms support China's most respected medical enterprises, research universities, and clinical centers.
Expert answers addressing the concerns of international purchasing leads, regulatory directors, and chief scientific officers.
MedGence delivers end-to-end preclinical and clinical development for plant-derived actives. This covers raw botanical screening, phenological potency mapping, development of HPTLC/HPLC testing methods, extraction process optimization, GLP safety toxicology, in vitro cell assays, validated in vivo disease models, human clinical trials (Phases I–IV), and commercial-scale OEM/CDMO production.
Yes. We manage both in-house research laboratories and directly operated pilot plants alongside partnered GMP production sites. Laboratory-optimized extraction protocols, column resin purification parameters, and crystal harvest kinetics transition into multi-ton manufacturing vessels under the supervision of the same technical team, preventing tech-transfer errors.
Method development relies on high-performance thin-layer chromatography (HPTLC) for qualitative identification, high-performance liquid chromatography (HPLC-DAD/ELSD), gas chromatography (GC-FID/MS), and multi-component chromatographic fingerprinting. Tests cross-reference United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Chinese Pharmacopoeia (ChP) guidelines.
We operate under a contract research and entrusted CDMO business model bound by confidentiality agreements (NDAs). Detailed formulation parameters, fraction ratios, and process conditions are strictly segregated on restricted project servers. Intellectual property generated during research belongs entirely to the commissioning sponsor.
For raw active substances, we produce concentrated vacuum liquid extracts, standardized spray-dried powders, purified resins, concentrated pastes, and steam-distilled volatile oils. Finished consumer dosage formats cover oral liquids, vegetarian and gelatin hard capsules, softgel capsules, coated tablets, effervescent powders, and soluble granules.
Yes. We structure localized, IRB/ethics-approved clinical trials ranging from small-scale pilot human cohorts (for dietary supplement health claims substantiation) up to GCP-compliant Phase I, Phase II, and Phase III multi-center clinical trials required for formal Botanical Drug Application (NDA) dossiers.
Directly access research protocols, testing packages, and OEM/ODM manufacturing partnerships for your formulation targets.
